PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis
Molecular Oncology · 2023
DOI: 10.1002/1878-0261.13539 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Xue Yang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University of Texas Health San Antonio, TX, USA. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Ribosomes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH Office of the Director, National Institues of Health, NCI NIH HHS.
Abstract (Originalsprache)
Endometrial carcinoma (ECa) is the fourth most common cancer among women. The oncogene PELP1 is frequently overexpressed in a variety of cancers, including ECa. We recently generated SMIP34, a small‐molecule inhibitor of PELP1 that suppresses PELP1 oncogenic signaling. In this study, we assessed the effectiveness of SMIP34 in treating ECa. Treatment of established and primary patient‐derived ECa cells with SMIP34 resulted in a significant reduction of cell viability, colony formation ability, and induction of apoptosis. RNA‐seq analyses showed that SMIP34‐regulated genes were negatively correlated with ribosome biogenesis and eukaryotic translation pathways. Mechanistic studies showed that the Rix complex, which is essential for ribosomal biogenesis, is disrupted upon SMIP34 binding to PELP1 . Biochemical assays confirmed that SMIP34 reduced ribosomal biogenesis and new protein synthesis. Further, SMIP34 enhanced the efficacy of mTOR inhibitors in reducing viability of ECa cells. SMIP34 is also effective in reducing cell viability in ECa organoids in vitro and explants ex vivo . Importantly, SMIP34 treatment resulted in a significant reduction of the growth of ECa xenografts. Collectively, these findings underscore the potential of SMIP34 in treating ECa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, University of Texas Health San Antonio, TX, USA.
- Department of Obstetrics and Gynecology, Second Xiangya Hospital, Central South University, Changsha, China.
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.
- Department of Obstetrics and Gynecology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, China.
- Mays Cancer Center, University of Texas Health San Antonio, TX, USA.
- Department of Biochemistry & Structural Biology, University of Texas Health San Antonio, TX, USA.
ORCID-Profile: Suryavathi Viswanadhapalli, Ratna K Vadlamudi
Förderung
- NIH Office of the Director
- National Institues of Health
- NCI NIH HHS
- NIH HHS
- NIH/NIGMS
- VA
- NIH Shared Instrument Grant
- Mays Cancer Center Support Grant
Zitieren
APA
Yang, X., Liu, Z., Tang, W., Pratap, U. P., Collier, A. B., Altwegg, K. A., Gopalam, R., Li, X., Yuan, Y., Zhou, D., Lai, Z., Chen, Y., Sareddy, G. R., Valente, P. T., Kost, E. R., Viswanadhapalli, S., & Vadlamudi, R. K. (2023). PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis. Molecular Oncology. https://doi.org/10.1002/1878-0261.13539
Vancouver
Yang X, Liu Z, Tang W, Pratap UP, Collier AB, Altwegg KA, et al. PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis. Molecular Oncology. 2023. doi:10.1002/1878-0261.13539
BibTeX
@article{Yang2023,
author = {Yang, Xue and Liu, Zexuan and Tang, Weiwei and Pratap, Uday P and Collier, Alexia B and Altwegg, Kristin A and Gopalam, Rahul and Li, Xiaonan and Yuan, Yaxia and Zhou, Daohong and Lai, Zhao and Chen, Yidong and Sareddy, Gangadhara R and Valente, Philip T and Kost, Edward R and Viswanadhapalli, Suryavathi and Vadlamudi, Ratna K},
title = {PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis},
journal = {Molecular Oncology},
year = {2023},
doi = {10.1002/1878-0261.13539}
}
EUVIMED